Clinical trial results shared by Boehringer Ingelheim and Insilico Medicine showed improvement in idiopathic pulmonary ...
Experts from the University of of Dundee's Centre for Targeted Protein Degradation (CeTPD), working with Boehringer Ingelheim ...
(Reuters) - The latest trial over claims that the discontinued heartburn drug Zantac causes cancer ended with a hung jury on ...
Boehringer's phase 3 lung fibrosis trial hits primary endpoint, teeing up filings for Ofev successor
Boehringer Ingelheim has ended a decade of industrywide failures in idiopathic pulmonary fibrosis (IPF) by reporting a phase ...
Boehringer is advancing the development of SZN-413 to prepare it for potential future clinical testingSZN-413 is a bi-specific antibody targeting ...
On Wednesday, a jury in Cook County Circuit Court in Illinois ended in a mistrial in a case against Zantac manufacturer ...
Boehringer Ingelheim announced today that the FIBRONEERTM-IPF trial met its primary endpoint, which was the absolute change ...
New research from the University of Dundee shows potential breakthrough for hard to treat cancers. Experts from the ...
The German big pharma will submit a new drug application to the US FDA after success at phase 3 for nerandomilast.
Boehringer Ingelheim’s investigational compound nerandomilast, which targets the PDE4B enzyme involved in fibrosis and ...
KRAS is the most mutated gene in cancer with mutations occurring in 17%–25% of all cancers, affecting millions of patients worldwide.
Boehringer Ingelheim pivotal phase-III FIBRONEER-IPF study of nerandomilast meets primary endpoint: Ingelheim, Germany Tuesday, September 17, 2024, 13:00 Hrs [IST] Boehringer Inge ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback